<?xml version="1.0" encoding="UTF-8"?>
<p id="p0090">The Poxvirus constructs are potent vectors due to better stability, greater insert size, easy production, cytoplasmic gene expression and capacity to elicit long-termed cell mediated and humoral immunity [
 <xref rid="bb0415" ref-type="bibr">83</xref>]. In a study, replication-compromised poxvirus vector, modified vaccinia Ankara (MVA) strain, coding for SARS-CoV S protein, generate neutralizing antibody response and reduced viral load in the upper airways of mice [
 <xref rid="bb0315" ref-type="bibr">63</xref>]. MVA constructs expressing entire S protein are potent vaccine target [
 <xref rid="bb0475" ref-type="bibr">[95]</xref>, 
 <xref rid="bb0480" ref-type="bibr">[96]</xref>, 
 <xref rid="bb0485" ref-type="bibr">[97]</xref>]. An additional vaccine target is MVA-MERS-S, presently in phase I clinical trial at University Medical Center Hamburg-Eppendorf, Germany [
 <xref rid="bb0490" ref-type="bibr">98</xref>]. Studies involving relatively conserved N protein expressing MVA in mice generated CD8
 <sup>+</sup> cells [
 <xref rid="bb0495" ref-type="bibr">99</xref>].
</p>
